Learn more from OA expertsWhat are the Risk Factors for Osteoarthritis?
JR: The projected cause of arthritis to society and the numbers that are increasing over the next 20 years are largely attributed to the growing and aging baby boomer population. SD: its more dynamic than that. Yes, aging is a risk factor for arthritis but there are other risk factors that are very common such as obesity, such as trauma and there is a large genetic component to the disease. And I say disease with the thought previously there was a wear and tear process but that is not very accurate, its actually a disease process that affects all aspects of the joint and there are multiple causes. JR: The knee joint is one of the most commonly affective joints that people come into an orthopaedics office complaining about arthritis related pain. And the primary reason is we don't give our knees a rest, we are on our knees all day, everyday. SD: it is subject to multiple stresses during the day and also gets major stresses in the form of injury and other disease processes JR: We think about carrying our body weight around but when you add physics equations to the problem, getting in and out of a chair, running up and down the stairs or jumping up and down on your knees, actually you are carrying multiples of your body weight around; five times, ten times your body weight depending upon the activity that you are doing. So that a weight gain of 10 pounds on the knee joint could be equivalent to 100 pounds of extra weight carried on the knees depending upon the level of activity that you are performing.
|
|
 |
EUFLEXXA (1% sodium hyaluronate) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics (eg, acetaminophen).
Important Safety Information EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride. Do not use skin disinfectants for skin preparation that contain quaternary ammonium salts. Do not inject intravascularly due to potential for systemic adverse events. The safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee have not been studied. Remove any joint effusion prior to injecting. Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA. The safety and effectiveness of repeated treatment cycles weeks with EUFLEXXA have not been established. In a randomized, double-blind, multicenter clinical trial (N=160 EUFLEXXA), the only adverse event reported with EUFLEXXA at an incidence greater than 5% was arthralgia (8.7%). Important Information for Patients. The information on this website is provided for educational purposes only. While there may be information on this web site related to certain medical conditions and their treatment, should a medical condition exist, promptly see your own physician or health provider as the information on this website is not intended to take the place of advice from a physician or healthcare professional. Ferring does not offer personalised medical diagnosis or patient-specific treatment advice. The statements made by doctors on this website represent their own individual experience and opinion and is not intended to be medical advice. Indeed, only your doctor or other health care professional, as a learned intermediary, can determine if a product described in this web site is appropriate for you. PLEASE CONSULT WITH YOUR DOCTOR, OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL BEFORE USING ANY PRODUCT DISCUSSED WITHIN THIS WEB SITE. This website is intended only for US residents.  
|
 |
||||||
